Complement-mediated kidney diseases

被引:37
|
作者
Poppelaars, Felix [1 ]
Thurman, Joshua M. [2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, AA53,Postbus 196, NL-9700 AD Groningen, Netherlands
[2] Univ Colorado Anschutz Med Campus, Div Nephrol & Hypertens, Aurora, CO USA
基金
美国国家卫生研究院;
关键词
Complement; Kidney; Glomerulonephritis; Therapeutics; HEMOLYTIC-UREMIC SYNDROME; MANNAN-BINDING LECTIN; H-RELATED PROTEINS; EXPERIMENTAL MEMBRANOUS NEPHROPATHY; DENSE DEPOSIT DISEASE; C3; GLOMERULOPATHY; ALTERNATIVE PATHWAY; IGA NEPHROPATHY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; POSTINFECTIOUS GLOMERULONEPHRITIS;
D O I
10.1016/j.molimm.2020.10.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It has long been known that the complement cascade is activated in various forms of glomerulonephritis. In many of these diseases, immune-complexes deposit in the glomeruli and activate the classical pathway. Researchers have also identified additional mechanisms by which complement is activated in the kidney, including diseases in which the alternative and lectin pathways are activated. The kidney appears to be particularly susceptible to activation of the alternative pathway, and this pathway has been implicated as a primary driver of atypical hemolytic uremic syndrome, C3 glomerulopathy, anti-neutrophil cytoplasmic antibody-associated vasculitis, as well as some forms of immune-complex glomerulonephritis. In this paper we review the shared and distinct mechanisms by which complement is activated in these different diseases. We also review the opportunities for using therapeutic complement inhibitors to treat kidney diseases.
引用
收藏
页码:175 / 187
页数:13
相关论文
共 50 条
  • [11] Complement C3-targeted therapy in C3 glomerulopathy, a prototype of complement-mediated kidney diseases
    Meuleman, Marie -Sophie
    Grunenwald, Anne
    Chauvet, Sophie
    SEMINARS IN IMMUNOLOGY, 2022, 60
  • [12] Immunoglobulin and complement-mediated glomerular diseases with a membranoproliferative glomerulonephritis pattern
    Hohenstein, B.
    Hugo, C.
    NEPHROLOGE, 2020, 15 (06): : 356 - 362
  • [13] NEW INSIGHTS INTO THE PATHOPHYSIOLOGY AND CLASSIFICATION OF COMPLEMENT-MEDIATED RENAL DISEASES
    Garam, Nora
    Szilagyi, Agnes
    Prohaszka, Zoltan
    Csuka, Dorottya
    MOLECULAR IMMUNOLOGY, 2019, 114 : 457 - 457
  • [14] Clusters Not Classifications: Making Sense of Complement-Mediated Kidney Injury
    Cook, H. Terence
    Pickering, Matthew C.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (01): : 9 - 12
  • [16] NEW INSIGHTS INTO THE PATHOPHYSIOLOGY AND CLASSIFICATION OF COMPLEMENT-MEDIATED RENAL DISEASES
    Garam, Nora
    Prohaszka, Zoltan
    Csuka, Dorotty
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34
  • [17] Factor B as a therapeutic target for the treatment of complement-mediated diseases
    Kavanagh, David
    Barratt, Jonathan
    Schubart, Anna
    Webb, Nicholas J. A.
    Meier, Matthias
    Fakhouri, Fadi
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [18] Was ist gesichert in der Therapie komplementvermittelter Nierenerkrankungen?What is proven in the treatment of complement-mediated kidney diseases?
    Jessica Kaufeld
    Svjetlana Lovric
    Die Innere Medizin, 2024, 65 (12) : 1216 - 1224
  • [19] HIF Stabilizer Desidustat Protects against Complement-Mediated Diseases
    不详
    DRUG RESEARCH, 2024, 74 (07) : 325 - 334
  • [20] A Diverse Spectrum of Immune Complex- and Complement-Mediated Kidney Diseases Is Associated With Mantle Cell Lymphoma
    Andeen, Nicole K.
    Abdulameer, Shahad
    Charu, Vivek
    Zuckerman, Jonathan E.
    Troxell, Megan
    Kambham, Neeraja
    Alpers, Charles E.
    Najafian, Behzad
    Nicosia, Roberto F.
    Smith, Kelly D.
    Kung, Vanderlene L.
    Avasare, Rupali S.
    Vallurupalli, Anusha
    Jefferson, J. Ashley
    Hecox, Douglas
    Swetnam, Leah
    Yamashita, Michifumi
    Lin, Mercury
    Bissonnette, Mei Lin
    Akilesh, Shreeram
    Hou, Jean
    KIDNEY INTERNATIONAL REPORTS, 2022, 7 (03): : 568 - 579